ANNE E. CALVARESI, MSN, RN, CRNP; EDOUARD J. TRABULSI, MD, FACS; MARYANN SONZOGNI, BSN, RN; LEONARD G. GOMELLA, MD, FACS; COSTAS D. LALLAS, MD, FACS; KRISTEN S. WACHSMUTH, DHSc, MBA, RN
Hexaminolevulinate HCl is a diagnostic imaging agent used with blue light during cystoscopy to help detect nonemuscle-invasive bladder cancer. Blue light cystoscopy performed using hexaminolevulinate HCl has been found to detect more papillary nonemuscle-invasive bladder tumors than cystoscopy performed using standard white light. Because bladder instillation and retention requirements of hexaminolevulinate during cystoscopy can affect patient flow in the perioperative setting, this technique necessitates changes in nursing practice and care of patients with known or suspected nonemuscle-invasive bladder cancer. Nursing personnel at one facility followed the AORN guidelines for preoperative patient care in the ambulatory setting to address staffing, preoperative nursing assessment, anesthesia evaluation, and preoperative teaching related to implementing blue light cystoscopy.
Log in to read the full article here: http://www.aornjournal.org/article/S0001-2092(14)00966-1/abstract